Trials / NCT06292650
Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients
Recruiting now Early Phase 1 Optogenetics, Gene therapy
- Sponsor
- Augelux Therapeutics
- Treatment
- ZM-02-L; ZM-02-H; ZM-02-S
- Gene
- Not gene-specific
- Conditions
- Retinitis Pigmentosa
- Ages
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Started
- 2024-02-25
- Main results expected
- 2027-12-25
- Results posted
- Not yet
- Record last updated
- 2026-03-31
What the study is testing
This is zM-02's safety, tOlerability, and efficacy in retinitis pigmentOsa first-in-humaN study (MOON). This trial is meant to evaluate the safety and efficacy of ZM-02 in Retinitis pigmentosa (RP) patients. Unilateral intravitreal injections (IVT) will be given into the subject's Study Eye.
Where it runs
China (1)
- Beijing Tongren Hospital of Capital Medical University, Beijing, Beijing Municipality (recruiting now)